Effects of C-peptide on Microvascular Blood Flow and Blood Hemorheology
2004

Effects of C-peptide on Blood Flow in Diabetes

publication 15 minutes Evidence: moderate

Author Information

Author(s): T. Forst, T. Kunt

Primary Institution: Institute for Clinical Research and Development, Mainz, Germany

Hypothesis

C-peptide supplementation may improve microvascular blood flow and erythrocyte deformability in type 1 diabetic patients.

Conclusion

C-peptide improves microvascular function and blood flow in type 1 diabetic patients by enhancing erythrocyte deformability and vascular regulation.

Supporting Evidence

  • C-peptide administration improved erythrocyte Na+K+ATPase activity by about 100%.
  • C-peptide supplementation increased nutritive capillary blood flow in type 1 diabetic patients.
  • Statistical analysis showed significant improvements in blood flow and erythrocyte deformability after C-peptide administration.
  • C-peptide enhanced nitric oxide release from endothelial cells, contributing to vasodilation.
  • Impaired Na+K+ATPase activity in diabetes was restored by C-peptide, improving blood flow.
  • C-peptide's effects on blood flow were observed in both in vitro and in vivo studies.
  • Type 1 diabetic patients showed a significant increase in capillary blood flow after C-peptide infusion.
  • C-peptide's effects were not observed in healthy controls, indicating its specific action in diabetic patients.

Takeaway

C-peptide helps blood flow in people with type 1 diabetes by making their blood cells more flexible and improving how their blood vessels work.

Methodology

The study involved in vitro and in vivo investigations assessing the effects of C-peptide on endothelial function, erythrocyte deformability, and microvascular blood flow in type 1 diabetic patients.

Potential Biases

Potential bias due to the study's focus on specific patient demographics and the reliance on certain methodologies.

Limitations

The study primarily focused on type 1 diabetes and may not be generalizable to other forms of diabetes.

Participant Demographics

Type 1 diabetic patients and healthy controls.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1080/15438600490424532

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication